Eurbio-Alport (RaDiCo Cohort) (RaDiCo Eurbio-Alport)

计划入组 700 人 · 首次发布于 2023 年 7 月 3 日

Efficacy and Safety of Qurevo Plus Ribavirin Based Therapy for Hepatitis C With or Without Cirrhosis in Haemodialysis Patients

计划入组 40 人 · 首次发布于 2017 年 3 月 1 日

QureBio Secures $14 Million Series C1 Funding to Advance Bispecific Antibody Pipeline

QureBio's Q-1802 Bispecific Antibody Shows 70% Response Rate in Advanced Gastric Cancer Phase II Trial

Viva's Portfolio Companies Announce Significant Advances in Biopharmaceutical Innovations